LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.

Recruiting Phase 3 Interventional Study
Autoimmune Hypothyroidism
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
600 (estimated)
Sponsor
M. Medici · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Hypothyroidism is common, affecting 5% of the general population, for which levothyroxine (LT4) monotherapy is the standard treatment. Despite normalized serum thyroid hormone levels, 10-15% of LT4 treated patients have various persistent complaints, the most important of which is tiredness. This could be explained by the fact that physiological T4/T3 ratios cannot be reached with LT4 monotherapy,…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients with overt or subclinical primary hypothyroidism 18 years or older.\* * LT4 monotherapy for at least 6 months. * LT4 monotherapy dose of 75-225 microg, with at least a dose of 1.2 microg/kg. * TSH levels within the assay-specific reference ranges for at least 3 months…
Contacts

Marco Medici, MD PhD

+31107043415

m.medici@erasmusmc.nl

CONTACT

Lizette Blankers, MD

+31636125982

l.blankers@erasmusmc.nl

CONTACT